Open Medicine Foundation Canada

Open Medicine Foundation Canada Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Open Medicine Foundation Canada, Nonprofit Organization, 2987 Baynes Road, Victoria, BC.

OMF Canada is working to create a world where people with chronic diseases like myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) live full, productive lives.

🧬 Science Wednesdays: Disease- vs symptom-modifying treatmentsSymptom-modifying treatments reduce the burden of specific...
06/10/2026

🧬 Science Wednesdays: Disease- vs symptom-modifying treatments

Symptom-modifying treatments reduce the burden of specific symptoms (e.g., cognitive dysfunction, pain, unrefreshing sleep). Disease-modifying treatments target the core mechanisms driving an illness, so they impact pathophysiology rather than just providing symptomatic relief.

How it applies in ME/CFS and Long COVID
As multi-system chronic complex diseases that lack a clear understanding of their underlying mechanism (or mechanisms), the majority of clinical care for ME/CFS and Long COVID focuses on symptom management. Research on these diseases often tries to identify treatable biological pathways, which may move the needle towards disease-modifying treatments. Translation of this type of research takes time, however, so disease-modifying approaches and symptom-modifying approaches—which may improve quality of life more quickly—both have value in ME/CFS and Long COVID.

OMF's vision is a world where ME/CFS, Long COVID, and related diseases are understood, rapidly diagnosed, and effectively treated—so every patient can live fully. Finding disease-modifying treatments is a major part of that vision, but we also want to make people better faster. Therefore, through our extensive research portfolio, we are simultaneously pursuing identifying disease- and symptom-modifying treatments.

Impact on research study design
Whether a study is exploring disease- or symptom-modifying treatments can have an impact on study design (the first stage of the research process) through the selection of outcome measures—how an effect is measured.

Symptom-modifying trials may prioritize patient-reported outcomes (e.g., surveys) to fully and accurately understand specific symptoms. Disease-modifying trials should pair clinical outcomes (e.g., function, post-exertional malaise, quality of life) with objective and mechanistic measures (e.g., autonomic testing, activity data, cardiopulmonary exercise testing) to demonstrate impact on underlying biology.

Read more about our research: https://www.omfcanada.ngo/end-me-cfs/

At the end of May, Open Medicine Foundation’s Founder and CEO, CRC Directors, and VP of Research Programs all attended t...
06/05/2026

At the end of May, Open Medicine Foundation’s Founder and CEO, CRC Directors, and VP of Research Programs all attended the 2026 Invest in ME Research Conference in Cambridge, UK. This annual event brings together researchers, clinicians, and advocates committed to advancing ME/CFS and Long COVID research worldwide.

After the conference, the OMF team gathered for a three-day, in-person meeting. The discussion topics included:

Standardization across all OMF projects,
Results from our recent CTN Lite patient and caregiver survey, and
Advanced scientific rationale for potential first treatment targets as part of CTN Lite.

These in-person gatherings help to facilitate collaborations and build momentum as we work to advance research on mechanisms, diagnosis, and treatment for ME/CFS and Long COVID.

Special thanks to all who attended this year:
Wenzhong Xiao, PhD, Computational Research Center for Complex Diseases
Jonas Bergquist, MD, PhD, Collaborative Center at Uppsala
Maureen Hansen, PhD
Linda Tannenbaum, Founder and CEO
Kimberly Hicks, COO and CFO
Danielle Meadows, PhD, VP of Research Programs and Operations
Janet Dafoe, PhD
Ron Davis, PhD, Collaborative Center at Stanford University
Christopher Armstrong, PhD, Melbourne ME/CFS Collaboration
Alain Moreau, PhD, Collaborative Center at Montreal

🧬Science Wednesdays: SubtypingSubtyping is the act of identifying smaller groups within a larger group of people. In the...
06/03/2026

🧬Science Wednesdays: Subtyping

Subtyping is the act of identifying smaller groups within a larger group of people. In the context of disease, subtypes are typically variations of the larger disease (e.g., HER2+ breast cancer is a subtype of breast cancer).

As ME/CFS is a heterogeneous disease, it’s likely that there are subtypes of the disease to identify. Subtyping might be particularly important for helping guide treatments.

OMF’s large-scale biomarker project, BioQuest, is working to incorporate subtype identification into its study. Read more about the project on our website: https://www.omfcanada.ngo/bioquest-large-scale-biomarker-project/

During day 2 of the Invest in ME Research Conference, Dr. Jonas Bergquist—Director of our Collaborative Center at Uppsal...
05/28/2026

During day 2 of the Invest in ME Research Conference, Dr. Jonas Bergquist—Director of our Collaborative Center at Uppsala—moderated a session on Biomarkers and Novel Pathways.

During the session, Dr. Ron Davis - Director of our Collaborative Center at Stanford - gave a presentation titled “Neutrophil Behavior - Evidence of Defective Host Response in ME/CFS”. The Director of our Computational Research Center for Complex Diseases, Dr. Wenzhong Xiao, also presented “Toward Treating PEM in ME/CFS."

05/28/2026

As May Momentum comes to a close, we want to leave you with a taste of why our researchers do what they do.

We are sharing a conversation that captures the heart of why this work matters and why there is real reason for hope. Danielle Meadows, PhD, our VP of Research Programs and Operations, recently connected with Ron Davis, PhD, Director of our Collaborative Center at Stanford, for a candid discussion. Watch the full conversation here: https://youtu.be/FPhECAf7gz0

Today at the Invest in ME Conference, Dr. Maureen Hanson — member of OMF's Scientific Advisory Board — presented "Search...
05/27/2026

Today at the Invest in ME Conference, Dr. Maureen Hanson — member of OMF's Scientific Advisory Board — presented "Searching for Chronic Infection in ME."

Thank you, Dr. Hanson, for the research that moves us closer to answers for the millions living with ME/CFS.

🧬Science Wednesdays: Autonomic nervous systemThe autonomic nervous system controls involuntary actions in the body like ...
05/27/2026

🧬Science Wednesdays: Autonomic nervous system

The autonomic nervous system controls involuntary actions in the body like heart rate, blood pressure, digestion, and more.

In ME/CFS, it is widely accepted that the autonomic nervous system doesn’t function correctly, which is called dysautonomia. This contributes to some of the major symptoms of ME/CFS, including fatigue.

OMF’s clinical trial, the Life Improvement Trial (LIFT), is investigating two drugs: pyridostigmine and low-dose naltrexone. Pyridostigmine has been used off-label to manage dysautonomia, so the LIFT may, in part, help to address dysautonomia in ME/CFS. Read more about the trial on our website: https://www.omf.ngo/the-life-improvement-trial/

In case you missed it!Linda Tannenbaum, Founder and CEO of Open Medicine Foundation, will deliver the inaugural lecture ...
05/22/2026

In case you missed it!

Linda Tannenbaum, Founder and CEO of Open Medicine Foundation, will deliver the inaugural lecture of Faculty of Medicine of the University of Lisbon’s new Open Lectures series on May 25.

📅 May 25
🕑 2:00 PM WEST
🕙 10:00 AM BRT
🕘 9:00 AM EST

📺 Watch live on YouTube:
FMUL YouTube Channel

Free and open to all. No registration required.

Linda Tannenbaum, Founder and CEO of Open Medicine Foundation, will deliver the inaugural lecture of Faculty of Medicine...
05/15/2026

Linda Tannenbaum, Founder and CEO of Open Medicine Foundation, will deliver the inaugural lecture of Faculty of Medicine of the University of Lisbon’s new Open Lectures series on May 25.

Her presentation, “Long COVID and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS): Research and Knowledge,” will explore the growing scientific understanding of ME/CFS and Long COVID and the urgent need for continued research progress.

📅 May 25
🕑 2:00 PM WEST
🕙 10:00 AM BRT
🕘 9:00 AM EST

📺 Watch live on YouTube:
FMUL YouTube Channel: https://www.youtube.com/

Free and open to all. No registration required.

One day left to take the CTN Lite survey.We know surveys take energy you don't always have. If you're able to give the C...
05/14/2026

One day left to take the CTN Lite survey.

We know surveys take energy you don't always have. If you're able to give the CTN Lite survey a few minutes before it closes tomorrow, your answers go directly to the researchers shaping what comes next for ME/CFS and Long COVID.

Every response counts. Take the survey here: https://forms.gle/1RAx657KFx9HoaLS9

Address

2987 Baynes Road
Victoria, BC
V8N1Y4

Alerts

Be the first to know and let us send you an email when Open Medicine Foundation Canada posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Open Medicine Foundation Canada:

Share